Teva Continues Divestitures To Close Allergan Deal With Product Sale To Impax
This article was originally published in The Pink Sheet Daily
Impax will gain 15 approved generics and three pipeline assets, which will help offset lower revenues of two of its existing top-sellers.
You may also be interested in...
Since Impax Laboratories’ CEO Wilkinson took the helm in April, the company has completed several significant deals and most recently restructured R&D to deliver savings, but a successful turnaround will require resolving outstanding manufacturing issues.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.